


Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOLTM PF for the Treatment of Presbyopia

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round

Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease

Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic
